Related Experiment Video
Updated: Aug 9, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Emerging Evidence on Membrane Estrogen Receptors as Novel Therapeutic Targets for Central Nervous System Pathologies
Agnieszka Wnuk1, Karolina Przepiórska1, Bernadeta Angelika Pietrzak1
1Laboratory of Neuropharmacology and Epigenetics, Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smetna Street 12, 31-343 Krakow, Poland.
Abstract:
Nuclear- and membrane-initiated estrogen signaling cooperate to orchestrate the pleiotropic effects of estrogens. Classical estrogen receptors (ERs) act transcriptionally and govern the vast majority of hormonal effects, whereas membrane ERs (mERs) enable acute modulation of estrogenic signaling and have recently been shown to exert strong neuroprotective capacity without the negative side effects associated with nuclear ER activity. In recent years, GPER1 was the most extensively characterized mER. Despite triggering neuroprotective effects, cognitive improvements, and vascular protective effects and maintaining metabolic homeostasis, GPER1 has become the subject of controversy, particularly due to its participation in tumorigenesis. This is why interest has recently turned toward non-GPER-dependent mERs, namely, mERα and mERβ. According to available data, non-GPER-dependent mERs elicit protective effects against brain damage, synaptic plasticity impairment, memory and cognitive dysfunctions, metabolic imbalance, and vascular insufficiency. We postulate that these properties are emerging platforms for designing new therapeutics that may be used in the treatment of stroke and neurodegenerative diseases. Since mERs have the ability to interfere with noncoding RNAs and to regulate the translational status of brain tissue by affecting histones, non-GPER-dependent mERs appear to be attractive targets for modern pharmacotherapy for nervous system diseases.
Insights
Estrogen signaling via membrane receptors (mERs) offers neuroprotection without nuclear ER side effects. Non-GPER-dependent mERs show promise for treating neurodegenerative diseases and stroke.
Area of Science:
- Endocrinology
- Neuroscience
- Pharmacology
Background:
- Estrogen signaling involves nuclear and membrane receptors (mERs) with distinct functions.
- Membrane ERs (mERs) mediate rapid signaling and neuroprotection, unlike classical nuclear ERs.
- G protein-coupled estrogen receptor 1 (GPER1) has shown benefits but is linked to tumorigenesis, prompting interest in other mERs.
Purpose of the Study:
- To explore the therapeutic potential of non-GPER-dependent membrane estrogen receptors (mERs).
- To investigate the neuroprotective and cognitive-enhancing roles of mERα and mERβ.
- To highlight mERs as novel targets for treating neurological disorders.
Main Methods:
- Review of existing literature on estrogen receptor signaling pathways.
- Analysis of studies investigating GPER1 and non-GPER-dependent mERs (mERα, mERβ).
- Evaluation of the impact of mERs on neuroprotection, synaptic plasticity, and cognitive function.
Main Results:
- Non-GPER-dependent mERs, specifically mERα and mERβ, demonstrate protective effects against brain damage and cognitive decline.
- These receptors influence synaptic plasticity, memory, and metabolic and vascular homeostasis.
- mERs interact with noncoding RNAs and regulate gene translation in brain tissue.
Conclusions:
- Non-GPER-dependent mERs offer neuroprotection and cognitive benefits without the adverse effects of nuclear ERs.
- These receptors represent promising therapeutic targets for stroke and neurodegenerative diseases.
- Targeting mERs could lead to novel pharmacotherapies for central nervous system disorders.
More Related Videos
Related Concept Videos
Neurotransmitters
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurochemical Transmission: Sites of Drug Action

